GH Research PLC (GHRS), a biopharmaceutical company focusing on psychiatric and neurological disorders, is nearing a key milestone with its lead drug candidate, GH001. Topline data from the Phase 2b trial of GH001 for treatment-resistant depression (TRD) in the EU and the United Kingdom are expected by the end of 2024 or the first quarter of 2025.
GH001, a proprietary inhaled formulation of mebufotenin (5-MeO-DMT), is being investigated for its potential to transform the treatment of psychiatric conditions. The Phase 2b trial is a critical step in evaluating the efficacy and safety of GH001 in patients who have not responded to conventional antidepressant therapies.
Additional Clinical Programs
Beyond TRD, GH001 is also being evaluated in two other Phase 2 single-arm trials:
- A trial in female patients with postpartum depression in the Netherlands and United Kingdom.
- A trial in participants with clinically diagnosed bipolar disorder type II experiencing a current episode of depression in the Netherlands and Germany.
These trials aim to explore the therapeutic potential of GH001 in a broader range of depressive disorders.
Aerosol Delivery Device and Regulatory Status
GH Research is also advancing its proprietary aerosol delivery device for GH001 administration, currently under evaluation in a Phase 1 clinical pharmacology trial in healthy volunteers in the UK. However, in the U.S., the company's investigational new drug application (IND) for GH001, administered via this device, is currently on clinical hold by the FDA. The company is actively working to address the FDA's concerns regarding the inhalation toxicology of the device.
Financial Position
As of September 30, 2024, GH Research reported a cash reserve of $193.8 million, providing financial runway to support its ongoing clinical programs.
